featured
Gemcitabine and Cisplatin ± Veliparib for Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation
J. Clin. Oncol 2020 Jan 24;[EPub Ahead of Print], EM O'Reilly, JW Lee, M Zalupski, M Capanu, J Park, T Golan, E Tahover, MA Lowery, JF Chou, V Sahai, R Brenner, HL Kindler, KH Yu, A Zervoudakis, S Vemuri, ZK Stadler, RKG Do, N Dhani, AP Chen, DP KelsenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.